局部晚期乳腺癌新辅助化疗的临床研究

目的探讨TA方案在局部晚期乳腺癌新辅助化疗应用中的临床疗效。方法对84例局部晚期乳腺癌采用新辅助化疗TA方案，共2-4个周期，分别测量化疗前后肿瘤体积的变化，评价疗效。结果新辅助化疗后84例中，临床完全缓解5例，部分缓解58例，无效19例，进展2例，总有效率75％。未发生严重毒副反应。结论TA方案是局部晚期乳腺癌新辅助化疗有效的方案，具有降低肿瘤分期，增加根治和保乳手术机会，值得临床推广。

Clinical research on neoadjuvant chemotherapy for locally advanced breast cancer

[Objective] To evaluate the clinical efficacy of TA(Paclitaxel+Adriamycin)in neoadjuvant chemotherapy for locally advanced breast cancer(LABC).[Methods] 84 cases with LABC were treated with TA regimen 2 to 4 cycles.The effect of TA regimen was assessed through the tumor volume variations.[Results] Among 84 cases received TA regimen,5 cases were in complete response(CR),58 cases were in partial response(PR),19 cases were in no change(NC)and 2 cases presented as progressive disease(PD).Total response rate(CR+PR)is 75%.No one had severe side effects.[Conclusion] The combination of Paclitaxel and Adriamycin(TA)is an effective regimen as neoadjuvant chemotherapy for the LABC.It can decrease the staging of tumors,enhance the chances of radical mastectomy and breast-conserving therapy.It has a good prospect of clinical application.